ABSTRACT To elucidate the mechanisms of action of nifedipine in angina pectoris, 14 patients were studied before and after sublingual administration of 10 mg nifedipine. Systemic and coronary hemodynamic and myocardial metabolic measurements were taken at rest and during pacing. At the pacing rate that induced pain in the control situation, no patient experienced angina after nifedipine administration. Lactate production during control turned into extraction after nifedipine administration (p < .05), and the double product was reduced (p < .001). Systemic and coronary vascular resistance were reduced by 26% (p < .001) and 19% (p < .005), respectively. Systolic blood pressure fell from 160 + 29 to 127 + 25 mm Hg (p < .001) and diastolic from 100 + 14 to 79 + 11 mm Hg (p < .001). Pulmonary artery diastolic blood pressure fell from 14 + 4 to 10 ± 3 mm Hg (p < .01). When the pacing rate was further increased after nifedipine administration until pain developed, the double product and the degree of lactate production were the same as during pain before nifedipine was administered. The pacing rate was 13 1 12 compared with 1 19 ± 13 during control (p < .001). Both the systolic and diastolic blood pressures were still significantly reduced compared with control pacing values, 131 + 26 mm Hg (p < .01) and 84 + 13 mm Hg (p < .01), respectively. Our data demonstrate that the antianginal efficiency can be partly explained by afterload reduction, which decreases myocardial oxygen consumption. The data also suggest additional mechanisms, possibly an increase in collateral flow, direct dilatation of stenotic parts of epicardial arteries, or a decrease in myocardial back pressure secondary to reduced left ventricular filling pressure.
NIFEDIPINE is a potent systemic and coronary arteriolar vasodilatorl 2 that blocks slow current calcium flux into the myocardial cells in isolated heart preparations.3-' In human studies the drug has proved to be effective both on exercise-induced and spontaneous angina pectoris .$ Angina at rest may be associated with coronary artery spasm,9 which causes myocardial ischemia by way of decreased oxygen supply. The beneficial effect of nifedipine on angina in patients with this type of angina is thought to be due to coronary vasodilation. 10 Whether this mechanism is responsible for pain relief in patients with exercise-induced angina is still unclear. Other factors, such as reduction of myocardial oxygen consumption through left ventricular unloading or decreased myocardial contractility, may be of importance. We performed this hemodynamic and myocardial metabolic study to elucidate 
Results
Systemic hemodynamics. The hemodynamic effects of nifedipine at rest are shown in table 2. Heart rate in- 4 . There was no change in coronary blood flow after nifedipine administration, but as a result of the drop in coronary perfusion pressure, the coronary vascular resistance fell significantly after nifedipine administration from 1 .38 ± 0.16 to 1. 12 ± 0.12 mm Hg/ml/min (p < .025).
Oxygen saturation in cardiac venous blood increased from 26.7 ± 1.4 to 35.2 ± 2.2% (p < .001).
The myocardial arteriovenous oxygen difference diminished significantly from 144.5 ± 5.0 to 122.1 ± 5.7 ml/l (p < .001), while the myocardial oxygen uptake remained essentially unchanged.
At The lactate extraction ratio during control pacing was -7 ± 5%. After nifedipine administration there was an improvement to 4 ± 4% (p < .05). Individual data show that nine patients exhibited myocardial lactate production in the control pacing situation. In four patients the lactate production ceased after nifedipine administration, decreased considerably in three, was unchanged in one (patient 3), and increased in one (patient 5) . As shown in figure 1, ST segment depression during pacing decreased from 2.0 ± 0.3 to 1.3 3 0.2 mm after nifedipine administration (p < .05).
Measurements were also performed during the higher pacing rate required to induce angina pectoris after nifedipine administration. These results are compared with control pacing values in table 6. Coronary sinus flow was not significantly altered but the coronary vascular resistance was still significantly lower compared with control, 0.97 + 0.09 and 0.76 + 0.07, respectively (p < .01). Oxygen saturation in arterial and coronary sinus blood was measured in eight patients. There was a slight decrease in arterial blood CIRCULATION AV-diff.
MVO2
MLEx (ml/min) (mm Hg/ml/min) (%) (%) (ml/l) (ml/min) tically significant. There was a similar degree of myocardial lactate production and ST segment depression compared with the control situation ( figure 1) .
The rate-pressure product in these eight patients decreased significantly at the same pacing rate after nifedipine administration but returned almost to control levels during pacing until angina pectoris occurred (figure 2).
Discussion
The present study has demonstrated a positive effect of nifedipine on pacing-induced angina pectoris in terms of increased tolerance to pacing, improved lactate metabolism, and less pronounced ST segment de- TABLE 6 pression. These beneficial effects are consistent with other pacing studies with nifedipine. '2 13 To explain these improvements, both direct cardiac effects and the influence of nifedipine on the systemic and coronary circulation must be taken into account. For this reason, possible mechanisms of action for angina relief are discussed below.
Myocardial contractility. In the isolated heart the nifedipine-induced inhibition of transmembraneous calcium flux decreases contractility.14 However, in human studies, nifedipine is known to increase this parameter, 15 AV-diff. MV02 MLEx (ml/min) (mm Hg/ml/min) These changes should decrease myocardial oxygen demand and there was a tendency, although not a significant one, for measured myocardial oxygen consumption to decrease. This ventricular unloading could be one major mechanism through which nifedipine prevented angina pectoris at the same heart rate that produced severe angina pectoris in the control situation. However, the effect on afterload is not the only explanation for the higher pacing rate required to induce angina after nifedipine administration. Angina pectoris developed at the same or slightly higher myocardial oxygen consumption rate as in the control situation. Also, the rate-pressure product was the same as that in the control situation, but with a higher heart rate and lower blood pressure after nifedipine administration. In this situation the diastolic perfusion time is shorter and the coronary perfusion pressure lower. These factors will impair perfusion to ischemic areas, where vasodilation should be maximal and coronary flow then dependent on perfusion pressure and length of diastolic period.20 If one assumes the same degree of stenosis in the coronary arteries in both situations, ischemnia and subsequent angina pectoris should instead have developed at a lower myocardial oxygen uptake and rate-pressure product. The fact that the patients could be paced to the same myocardial oxygen consumption and rate-pressure product after nifedipine administration as in the control situation in spite of reduced perfusion pressure and shorter diastolic periods, strongly suggests that coronary flow to the poststenotic areas was enhanced. It seems likely that a direct effect of nifedipine on the coronary vascular bed caused this improvement of flow.
Coronary vasodilatation. Coronary vascular resistance was markedly reduced after nifedipine administration, which resulted in an increased coronary flow in relation to myocardial oxygen demand; this was reflected in a significant increase in oxygen saturation in the coronary sinus blood. However, a pharmacologically induced decrease in overall coronary vascular resistance is not necessarily beneficial to patients with angina pectoris. It has been demonstrated that generalized dilatation of resistance vessels in the presence of multiple stenosis could cause a maldistribution of coronary flow away from the ischemic area. Such unfavorable effects have been particularly ascribed to drugs acting predominantly on resistance vessels and these effects have been demonstrated for nitroprusside, dipyridamole, and carbocromen.21 23 Since nifedipine also is a coronary arteriolar dilator, the risk for coronary steal must be considered and might explain why two of our patients did not have diminished myocardial lactate production. However, as for the rest of the patients this side effect, if present, evidently was counterbalanced by other mechanisms. For example, nifedipine has been shown to increase collateral flow to ischemic areas in animal experiments.24 It is thus conceivable that some component of the favorable effect seen in our patients was related to a dilatory action on collateral vessels.
Another possible explanation is that nifedipine administration could influence the degree of stenosis. This might be especially important if the vascular tone is inappropriately high, either locally at the site of the stenosis or generally in the vascular wall. It has recently been shown that nitroglycerine causes stenosis dilatation and that this might be important for the beneficial action of the drug.25 If this is true for nifedipine as well, the flow to the underperfused areas could have increased through this mechanism in our patients and thus relieved angina pectoris.
A third possibility is that, through the decrease in left ventricular end-diastolic pressure, nifedipine caused a decrease in myocardial back-pressure that resulted in an improved perfusion pressure distal to coronary artery stenosis.6 In our study, the low level of filling pressure in the left ventricle and the small changes in filling pressure as reflected in pulmonary diastolic pressure makes this explanation less likely.
Coronary sinus flow measurements do not give any information as to the regional flow or collateral flow. Even if our data strongly suggest that mechanisms other than ventricular unloading have been operating, our data do not show which of these additional mechanisms might have been activated.
In conclusion, nifedipine was effective on pacinginduced angina in patients with severe coronary artery disease who were on long-term,f-blocker therapy. Unloading of the left ventricle seems to be one major mechanism to explain this favorable effect. Our data suggest additional mechanisms that could be an increase in collateral flow, direct dilatation of stenotic parts of epicardial arteries, or a decrease in myocardial back-pressure secondary to reduced left ventricular filling pressure, or a combination of these.
